Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin sudelidec
- Development stage
- Phase 3
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
Insulin sudelidec, also known by its code name INS068 and brand name Shudi Insulin Injection, is a novel, soluble, long-acting insulin analog developed by Jiangsu HengRui Medicine Co., Ltd. It functions as an insulin receptor agonist, designed to provide stable and prolonged blood glucose-lowering effects. This pharmaceutical drug is intended for the treatment of both type 1 and type 2 diabetes mellitus, aiming to cover basal insulin requirements. Clinical trials have shown its efficacy and safety profiles to be comparable to existing long-acting insulin analogs like insulin glargine and insulin degludec.
- Brand names
- Shudi Insulin Injection
- Other names
- INS068 injectionINS-068 injectionINS 068 injection
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on insulin sudelidec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin sudelidec.